In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beth Israel Deaconess Medical Center

www.bidmc.org

Latest From Beth Israel Deaconess Medical Center

Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie

French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.

Deals M & A

Obesity 2016: Minimally Invasive Bariatric Devices Gaining Steam

With no end in sight for the obesity epidemic, there is a vast and underserved market opportunity for manufacturers developing minimally invasive solutions for obesity that can fill the treatment gap between invasive bariatric surgery and conservative weight loss methods (diet, exercise, and drugs). Despite some high-profile setbacks in the last few years, the market for minimally invasive bariatric devices is gaining steam as several companies have recently launched obesity devices on the US market while others have completed clinical trials and are advancing toward US regulatory approval.

Gastrointestinal Metabolic Disorders

Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role

Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.

Commercial Innovation

Making The Grade? Big Pharma Deals With Academia Begin To Score

With three to four years in the books, Big Pharma’s updated tie-ups with academia have started to progress – some have even reached first-in-human stages, but these updated models have yet to produce any radical results that show they are an improvement over old-style partnerships.

BioPharmaceutical Strategy
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register